De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Jiangsu Nhwa Pharmaceutical Beheer

Beheer criteriumcontroles 3/4

De CEO Jiangsu Nhwa Pharmaceutical's is Jiaquan Sun, benoemd in May2013, heeft een ambtstermijn van 11.42 jaar. bezit rechtstreeks 0.07% van de aandelen van het bedrijf, ter waarde CN¥ 19.38M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 11.4 jaar en 17.5 jaar.

Belangrijke informatie

Jiaquan Sun

Algemeen directeur

CN¥4.8m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	11.4yrs
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	11.4yrs
Gemiddelde ambtstermijn bestuur	17.5yrs

Recente managementupdates

Recent updates

CEO

Jiaquan Sun (48 yo)

11.4yrs

Tenure

CN¥4,800,000

Compensatie

Mr. Jiaquan Sun has been General Manager at Jiangsu Nhwa Pharmaceutical Co., Ltd. since May 31, 2013 and has been its Non-Independent Director since April 1, 2019. Mr. Sun serves as General Manager of Jian...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jiaquan Sun	GM & Non-Independent Director	11.4yrs	CN¥4.80m	0.070% CN¥ 19.2m
Gangsheng Li	Chief Financial Officer	2yrs	CN¥633.60k	geen gegevens
Qing Fu	Deputy GM & Non-Independent Director	11.4yrs	CN¥200.00k	3.93% CN¥ 1.1b
Zengliang Chen	Deputy GM & Non-Independent Director	11.4yrs	CN¥200.00k	3.93% CN¥ 1.1b
Ziliang Yang	Deputy GM & Non-Independent Director	11.4yrs	CN¥200.00k	3.69% CN¥ 1.0b
Bao Zhou Duan	Deputy GM & Secretary	11.4yrs	CN¥413.70k	0.0053% CN¥ 1.4m

11.4yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 002262 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 11.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jiaquan Sun	GM & Non-Independent Director	14.4yrs	CN¥4.80m	0.070% CN¥ 19.2m
Qing Fu	Deputy GM & Non-Independent Director	17.5yrs	CN¥200.00k	3.93% CN¥ 1.1b
Zengliang Chen	Deputy GM & Non-Independent Director	17.5yrs	CN¥200.00k	3.93% CN¥ 1.1b
Ziliang Yang	Deputy GM & Non-Independent Director	17.5yrs	CN¥200.00k	3.69% CN¥ 1.0b
Pengsheng Sun	Non-Independent Chairman of the Board	17.5yrs	CN¥250.00k	4.87% CN¥ 1.3b
Guangji Wang	Independent Director	5.6yrs	CN¥50.00k	geen gegevens
Yu Lan Li	Independent Director	2.5yrs	CN¥50.00k	geen gegevens
Fengshou Wang	Chairman of the Supervisory Board	17.5yrs	geen gegevens	geen gegevens
Xinglei Jia	Member of the Supervisory Board	17.5yrs	geen gegevens	geen gegevens
Xiao Chen Qian	Employee Representative Member of Supervisory Board	17.5yrs	geen gegevens	geen gegevens
Xiaoxing Yin	Independent Director	2.5yrs	CN¥50.00k	geen gegevens
Guoxiang Chen	Independent Director	2.5yrs	CN¥50.00k	geen gegevens

17.5yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 002262 zijn ervaren en ervaren (gemiddelde ambtstermijn van 17.5 jaar).

Jiangsu Nhwa Pharmaceutical Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 24, 2024

High number of new directors

Jiangsu Nhwa Pharmaceutical Co., LTD Approves the Election of Chen Guoxiang and Li Yulan as Independent Directors

Insufficient new directors

Insufficient new directors

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 29, 2022

Recent updates

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Q3, 2024 Results on Oct 26, 2024

Now 20% undervalued

Second quarter 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.31 in 2Q 2023)

Jiangsu Nhwa Pharmaceutical Co., LTD to Report First Half, 2024 Results on Jul 31, 2024

Now 21% overvalued

Full year 2023 earnings released: EPS: CN¥1.03 (vs CN¥0.89 in FY 2022)

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 24, 2024

Investor sentiment deteriorates as stock falls 17%

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.30 in 3Q 2022)

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: CN¥0.31 (vs CN¥0.25 in 2Q 2022)

Jiangsu Nhwa Pharmaceutical Co., LTD to Report First Half, 2023 Results on Jul 31, 2023

Jiangsu Nhwa Pharmaceutical Co., Ltd. Receives Formal Approval from the National Medical Products Administration for OLINVYK

Full year 2022 earnings released: EPS: CN¥0.89 (vs CN¥0.79 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.30 (vs CN¥0.26 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.24 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.24 in 2Q 2021)

High number of new directors

Jiangsu Nhwa Pharmaceutical Co., LTD Approves the Election of Chen Guoxiang and Li Yulan as Independent Directors

First quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.17 in 1Q 2021)

Insufficient new directors

Insufficient new directors

Full year 2021 earnings released: EPS: CN¥0.79 (vs CN¥0.72 in FY 2020)

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 29, 2022

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 29, 2022

Jiangsu Nhwa Pharmaceutical Co., Ltd Proposes Cash Dividend for 2021

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.21 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.21 in 2Q 2020)

Jiangsu Nhwa Pharmaceutical Co., Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 02 June 2021

First quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.14 in 1Q 2020)

New 90-day low: CN¥13.53

Full year 2020 earnings released: EPS CN¥0.72 (vs CN¥0.66 in FY 2019)

Revenue beats expectations

New 90-day low: CN¥14.10

Investor sentiment deteriorated over the past week

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Fiscal Year 2020 Results on Mar 12, 2021

New 90-day low: CN¥15.46

New 90-day high: CN¥18.50

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: CN¥15.34

New 90-day low - CN¥15.61

New 90-day high - CN¥18.57

Jiangsu Nhwa Pharmaceutical Co., LTD to Report First Half, 2020 Results on Jul 31, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd